Your Messages Inbox
Your Article Summary
See Latest ArticlesDaiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient
Daiichi Sankyo, 08/17/09
Daiichi Sankyo, Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Effient (prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with an artery–opening procedure known as percutaneous coronary intervention (PCI). PCI usually includes the placement of a stent to help keep the artery open.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
Novartis, 11/30/09
Major European regulatory milestone in cardiovascular protection for Micardis : Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients
Boehringer Ingelheim, 11/30/09
Human genome sciences submits biologics license application to fda for zalbin
Human Genome Sciences, 11/30/09
Article Search
Sponsor